Mycophenolate mofetil is rapidly absorbed in the upper digestive tract after oral administration. The main site of absorption is in the stomach and is metabolized by plasma lipase to the pharmacologically active product mycophenolic acid (MPA), with an average bioavailability of 94%. The blood concentration peaked rapidly after 1 hour of taking the drug, and then dropped rapidly. MPA is metabolized by glucuronidation in the liver to stable, non-pharmacologically active glucuronide (MPAG), which is excreted in the urine. MPAG excreted by bile in the intestine enters the small intestine, and the glucosidase of the intestinal flora converts it into MPA, which is reabsorbed through the intestine to form enterohepatic circulation, and the second plasma MPA peak occurs (6~12 hours after taking). About 6% of MPAG is excreted in feces.
Mycophenolate mofetil (MMF) is mainly used to prevent organ rejection in allogenes. Mainly kidney transplantation, it is also suitable for heart and liver transplantation, especially refractory rejection after transplantation.
|Appearance||White or almost white crystalline powder||Conform|
|Residue on ignition||≤0.1%||Conform|
|Assay||98.0% - 102.0%||99.7%|
|Appearance:||White or almost white crystalline powder|
|Package details:||1kg/foil bag;10kg/drum|
Guaranteed the purity
High quality & competitive price
Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!